Frequency of serious adverse events and death in 5-17 months children receiving RTS, S/AS01E vaccine-a systematic review and meta-analysis of RCTs.
AZ Bindzi, RN Linjouom, MN Ndongo, JR Nkeck, L Yan… - 2024 - researchsquare.com
Background The RTS, S/AS01E vaccine has been authorized for use in children in sub-
Saharan Africa from the age of 5 months. Nevertheless, there is a limited number of clinical …
Saharan Africa from the age of 5 months. Nevertheless, there is a limited number of clinical …
Malaria vaccine-related adverse events among children under 5 in sub-Saharan Africa: systematic review and meta-analysis protocol
K Ohene-Adjei, KP Asante, KO Akuffo, N Tounaikok… - BMJ open, 2023 - bmjopen.bmj.com
Introduction The RTS, S vaccine has been approved for use in children under 5 living in
moderate to high malaria transmission areas. However, clinically important adverse events …
moderate to high malaria transmission areas. However, clinically important adverse events …
Safety and immunogenicity performance of RTS, S/AS01 and RTS, S/AS02 malaria vaccines in sub-Saharan African children: a systematic review and meta-analysis …
SM Dyrkorn - 2022 - ntnuopen.ntnu.no
Introduction: Despite being preventable and treatable, malaria remains a major global
health concern, with 627 000 deaths caused by malaria in 2020. The global burden of P …
health concern, with 627 000 deaths caused by malaria in 2020. The global burden of P …
Safety profile of the RTS, S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa
Y Guerra Mendoza, E Garric, A Leach… - Human vaccines & …, 2019 - Taylor & Francis
ABSTRACT A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-
Saharan Africa showed RTS, S/AS01 vaccine efficacy against malaria. We now present in …
Saharan Africa showed RTS, S/AS01 vaccine efficacy against malaria. We now present in …
Efficacy of RTS, S/AS01E vaccine against malaria in children 5 to 17 months of age
Background Plasmodium falciparum malaria is a pressing global health problem. A previous
study of the malaria vaccine RTS, S (which targets the circumsporozoite protein), given with …
study of the malaria vaccine RTS, S (which targets the circumsporozoite protein), given with …
Acceptance, availability, and feasibility of RTS, S/AS01 malaria vaccine: a review
H Mumtaz, A Nadeem, W Bilal, F Ansar… - Immunity …, 2023 - Wiley Online Library
Introduction In malaria‐stricken regions, malaria continues to be one of the primary causes
of mortality for children. The number of malaria‐related fatalities has drastically decreased …
of mortality for children. The number of malaria‐related fatalities has drastically decreased …
Long-term incidence of severe malaria following RTS, S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 …
Background Results from a previous phase 3 study showed efficacy of the RTS, S/AS01
vaccine against severe and clinical malaria in children (in 11 sites in Africa) during a 3–4 …
vaccine against severe and clinical malaria in children (in 11 sites in Africa) during a 3–4 …
RTS, S/AS01 malaria vaccine—proven safe and effective?
A Björkman, CS Benn, P Aaby… - The Lancet Infectious …, 2023 - thelancet.com
In October, 2021, WHO recommended that the RTS, S malaria vaccine, with its strong safety
profile and high impact, be provided to children from age 5 months in regions with moderate …
profile and high impact, be provided to children from age 5 months in regions with moderate …
Safety of the Malaria Vaccine Candidate, RTS,S/AS01E in 5 to 17 Month Old Kenyan and Tanzanian Children
The malaria vaccine candidate, RTS, S/AS01E, showed promising protective efficacy in a
trial of Kenyan and Tanzanian children aged 5 to 17 months. Here we report on the …
trial of Kenyan and Tanzanian children aged 5 to 17 months. Here we report on the …
Design of a phase III multicenter trial to evaluate the efficacy of the RTS, S/AS01 malaria vaccine in children across diverse transmission settings in Africa
A Leach, J Vekemans, M Lievens, O Ofori-Anyinam… - Malaria journal, 2011 - Springer
Abstract Background GlaxoSmithKline Biologicals and the PATH Malaria Vaccine Initiative
are working in partnership to develop a malaria vaccine to protect infants and children living …
are working in partnership to develop a malaria vaccine to protect infants and children living …